Company: NDRA
Filing Date: 2025-03-31
Form Type: 10-K
Source: 0001654954-25-003612
Chunk: 1023

Company: ENDRA Life Sciences Inc.
Filing Date: 2025-03-31
Form: 10-K
Item: Item 9C
Chunk 1023
---
 other than the individual who served as our principal executive officer during 2024, and up to two additional individuals for whom disclosure would have been provided but for the fact that such individual was not serving as an executive officer at the end of the last completed fiscal year (collectively, the “named executive officers”):

2024 Summary Compensation Table

Name and PrincipalPosition Year Salary ($)  Option Awards ($) (1)  Non-equity Incentive Plan Compensation ($)  All Other Compensation ($)(2)  Total ($) Alexander Tokman 2024  114,231   954(3)  -   100,000(3)  215,185 Acting Chief Executive Officer (since August 13, 2024)                      Francois Michelon   2024  202,126   -   -   112,524(4)  314,650 Former Chief Executive Officer (until August 12, 2024) 2023  387,859   258,341   -   587   646,787 Michael Thornton (5) 2024  221,690   -   -   392   222,082 Chief Technology Officer 2023  278,851   252,734   -   392   531,977 Richard Jacroux 2024  95,900   -   -   -   95,900(6)Chief Financial Officer (since August 8, 2024)                      Irina Pestrikova 2024  126,298   -   -   -   126,298 Former Senior Director, Finance (until August 8, 2024) 2023  185,000   29,724   -   -   214,724 

______________

(1) The amounts shown in this column indicate the grant date fair value of option awards granted in the subject year computed in accordance with FASB ASC Topic 718. For additional information regarding the assumptions made in calculating these amounts, see notes 2 and 8 to the financial statements included in Part II, Item 8 of this Annual Report. The shares underlying these option awards vest and become exercisable in three equal annual installments beginning on the first anniversary of their respective grant dates.(